Literature DB >> 24608070

Novel vaccine approaches for protection against intracellular pathogens.

Kristin L Griffiths1, Shabaana A Khader2.   

Abstract

Vaccination against intracellular pathogens requires generation of a pool of memory T cells able to respond upon infection and mediate either killing of the infected cell or induce killing mechanisms in the infected cell. T cell-inducing vaccines must aim to target the antigen to antigen-presenting cells (APCs) so that it can be presented on MHC molecules on the cell surface. Methods to do this include making use of vectors such as plasmid DNA or viruses, live attenuated pathogens or subunit vaccines targeted and enhanced using adjuvants. The choice of approach should be guided by the phenotype and localization of the desired T cell response. This review will discuss current approaches in the pipeline for the development of T cell-inducing vaccines, including vectored, live attenuated, and subunit vaccines.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24608070      PMCID: PMC4037333          DOI: 10.1016/j.coi.2014.02.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  52 in total

1.  Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory.

Authors:  Jonathan K Nambiar; Rachel Pinto; Juan I Aguilo; Kiyoshi Takatsu; Carlos Martin; Warwick J Britton; James A Triccas
Journal:  Eur J Immunol       Date:  2011-12-27       Impact factor: 5.532

2.  The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; Jes Dietrich; Esterlina Tan; Rodolfo M Abalos; Jasmin Burgos; Carolyn Bigbee; Matthew Bigbee; Leslie Milk; Hannah P Gideon; Mark Rodgers; Catherine Cochran; Kristi M Guinn; David R Sherman; Edwin Klein; Christopher Janssen; JoAnne L Flynn; Peter Andersen
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.

Authors:  Daniel F Hoft; Azra Blazevic; Jaime Stanley; Bernard Landry; Donata Sizemore; Eloi Kpamegan; Jacqueline Gearhart; Alison Scott; Sandra Kik; Maria G Pau; Jaap Goudsmit; J Bruce McClain; Jerald Sadoff
Journal:  Vaccine       Date:  2012-01-30       Impact factor: 3.641

Review 4.  Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.

Authors:  Joseph U Igietseme; Francis O Eko; Carolyn M Black
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

5.  A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.

Authors:  Kari A Sweeney; Dee N Dao; Michael F Goldberg; Tsungda Hsu; Manjunatha M Venkataswamy; Marcela Henao-Tamayo; Diane Ordway; Rani S Sellers; Paras Jain; Bing Chen; Mei Chen; John Kim; Regy Lukose; John Chan; Ian M Orme; Steven A Porcelli; William R Jacobs
Journal:  Nat Med       Date:  2011-09-04       Impact factor: 53.440

Review 6.  Tularemia vaccines: recent developments and remaining hurdles.

Authors:  J Wayne Conlan
Journal:  Future Microbiol       Date:  2011-04       Impact factor: 3.165

7.  Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Authors:  Martin O C Ota; Aderonke A Odutola; Patrick K Owiafe; Simon Donkor; Olumuyiwa A Owolabi; Nathaniel J Brittain; Nicola Williams; Sarah Rowland-Jones; Adrian V S Hill; Richard A Adegbola; Helen McShane
Journal:  Sci Transl Med       Date:  2011-06-22       Impact factor: 17.956

8.  Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Authors:  Stefano Colloca; Eleanor Barnes; Antonella Folgori; Virginia Ammendola; Stefania Capone; Agostino Cirillo; Loredana Siani; Mariarosaria Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Maria Ambrosio; Angela Sparacino; Marta Bartiromo; Annalisa Meola; Kira Smith; Ayako Kurioka; Geraldine A O'Hara; Katie J Ewer; Nicholas Anagnostou; Carly Bliss; Adrian V S Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

9.  Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

Authors:  Saumyabrata Mazumder; Mithun Maji; Nahid Ali
Journal:  PLoS Negl Trop Dis       Date:  2011-12-20

10.  Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses.

Authors:  Christiane Desel; Anca Dorhoi; Silke Bandermann; Leander Grode; Bernd Eisele; Stefan H E Kaufmann
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

View more
  24 in total

1.  A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.

Authors:  Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

3.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

Review 4.  Neonatal Vaccination: Challenges and Intervention Strategies.

Authors:  Matthew C Morris; Naveen Surendran
Journal:  Neonatology       Date:  2016-01-13       Impact factor: 4.035

Review 5.  Listening to each other: Infectious disease and cancer immunology.

Authors:  Russell E Vance; Michael J Eichberg; Daniel A Portnoy; David H Raulet
Journal:  Sci Immunol       Date:  2017-01-13

6.  Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens.

Authors:  Katarzyna Kuczkowska; Charlotte R Kleiveland; Rajna Minic; Lars F Moen; Lise Øverland; Rannei Tjåland; Harald Carlsen; Tor Lea; Geir Mathiesen; Vincent G H Eijsink
Journal:  Appl Environ Microbiol       Date:  2016-12-30       Impact factor: 4.792

7.  Mycobacterium tuberculosis HspX/EsxS Fusion Protein: Gene Cloning, Protein Expression, and Purification in Escherichia coli.

Authors:  Farzad Khademi; Arshid Yousefi-Avarvand; Mohammad Derakhshan; Zahra Meshkat; Mohsen Tafaghodi; Kiarash Ghazvini; Ehsan Aryan; Mojtaba Sankian
Journal:  Rep Biochem Mol Biol       Date:  2017-10

8.  Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.

Authors:  Mushtaq Ahmed; Hongmei Jiao; Racquel Domingo-Gonzalez; Shibali Das; Kristin L Griffiths; Javier Rangel-Moreno; Uma M Nagarajan; Shabaana A Khader
Journal:  J Leukoc Biol       Date:  2017-03-03       Impact factor: 4.962

9.  Cutting Edge: Protection by Antiviral Memory CD8 T Cells Requires Rapidly Produced Antigen in Large Amounts.

Authors:  Sanda Remakus; Xueying Ma; Lingjuan Tang; Ren-Huan Xu; Cory Knudson; Carolina R Melo-Silva; Daniel Rubio; Yin-Ming Kuo; Andrew Andrews; Luis J Sigal
Journal:  J Immunol       Date:  2018-04-11       Impact factor: 5.422

Review 10.  Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease.

Authors:  Yong Taik Lim
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.